Skip to main content
Camila Masias, MD, Hematology, Miami, FL, Baptist Hospital of Miami


Hematology Miami, FL

Clotting Disorder, Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology


Overview of Dr. Masias

I am a board certified hematologist and medical oncologist. I completed my training at the Ohio State University - James Comprehensive Cancer Center, where I also completed a Masters in Public Health with an emphasis in clinical and translational research. I devote my clinical practice to the field of classical hematology, and have a research interest in thrombotic microangiopathies and platelet disorders.

Education & Training

  • The Ohio State University
    The Ohio State University Master of Public Health, Clinical and Translational Research , 2017 - 2019
  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2015 - 2018
  • Icahn School of Medicine at Mount Sinai (Beth Israel)
    Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Internal Medicine, 2011 - 2014
  • Cayetano Heredia University
    Cayetano Heredia UniversityClass of 2008

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2019 - 2026
  • OH State Medical License
    OH State Medical License 2015 - 2021
  • NY State Medical License
    NY State Medical License 2014 - 2016
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Clinical Research Training Insitute American Society of Hematology, 2019
  • Outstanding Clinical Care Award The Ohio State University, hematology and Oncology fellowship, 2018

Publications & Presentations


Journal Articles

  • The Role of ADAMTS13 Testing in the Diagnosis and Management of Thrombotic Microangiopathies and Thrombosis  
    Spero R Cataland, Camila Masias, Blood


  • Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy
    Camila Masias, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019


  • A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

  • ASH 22 Presentation Preview: Most/All Patients With Acquired (Immune) Thrombotic Thrombocytopenic Purpura Receive CaplacizumabDecember 2022

Professional Memberships

Other Languages

  • Spanish

Hospital Affiliations